Rapid Molecular Diagnostics Enables Individualized Frontline Treatment of CBFA2T3::GLIS2-Rearranged Acute Myeloid Leukemia.

Published 07/25/2026

Research record: Rapid Molecular Diagnostics Enables Individualized Frontline Treatment of CBFA2T3::GLIS2-Rearranged Acute Myeloid Leukemia.

Published in Pediatr Blood Cancer; first publication date 2026-07-25. PMID 42500906.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-07-25

Updated

2026-10-20

Disclaimer

professional use

References